Regenxbio RGNX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $6.39M-78.9% | $30.34M+2.0% | $29.73M+39.2% | $21.36M-76.0% | $89.01M+320% | ||
| $57.34M-3.8% | $59.61M+6.3% | $56.1M-5.7% | $59.5M+12.1% | $53.09M+5.4% | ||
| $21.31M-4.8% | $22.38M+10.5% | $20.25M+1.9% | $19.88M-2.3% | $20.35M+1.5% | ||
| $89.76M+2.0% | $87.97M+7.1% | $82.14M-2.9% | $84.64M+10.1% | $76.89M+5.9% | ||
| -$83.36M-44.6% | -$57.64M-10.0% | -$52.41M+17.2% | -$63.28M-622% | $12.13M+124% | ||
| -1,304%-1,114pp | -190%-13.7pp | -176.3%+120pp | -296.3%-310pp | 13.6%+256pp | ||
| $8.71M-29.1% | $12.28M-6.8% | $13.17M+19.8% | $10.99M+28.3% | $8.57M-9.0% | ||
| $2M-27.0% | $2.75M-24.2% | $3.62M+7.1% | $3.38M+35.1% | $2.5M-73.7% | ||
| -$6.69M+29.7% | -$9.51M+0.2% | -$9.53M-25.5% | -$7.59M-25.6% | -$6.04M-3,421% | ||
| -$90.05M-34.1% | -$67.15M-8.4% | -$61.94M+12.6% | -$70.87M-1,265% | $6.08M+112% | ||
| -1,408.6%-1,187pp | -221.3%-13.0pp | -208.3%+123pp | -331.8%-339pp | 6.8%+248pp | ||
| -$1.72-32.3% | -$1.30-8.3% | -$1.20+13.0% | -$1.38-1,250% | $0.12+112% | ||
| -$1.72-32.3% | -$1.30-8.3% | -$1.20+13.0% | -$1.38-1,250% | $0.12+112% | ||
| 52.4M+1.7% | 51.6M-0.2% | 51.7M+0.4% | 51.5M+0.1% | 51.4M+3.9% | ||
| 52.4M+1.7% | 51.6M-0.2% | 51.7M+0.4% | 51.5M+0.2% | 51.4M+3.7% | ||
| $11.07M+86.8% | $5.93M+3.5% | $5.73M+9.9% | $5.21M+51.6% | $3.44M-45.6% | ||
| -$36K+33.3% | -$54K+16.9% | -$65K-44.4% | -$45K-200% | -$15K+98.2% | ||
| $16K-11.1% | $18K-5.3% | $19K-9.5% | $21K-16.0% | $25K-69.9% | ||
| -$90.23M-34.3% | -$67.18M-8.6% | -$61.84M+12.7% | -$70.86M-1,269% | $6.06M+112% | ||
| $2M-27.0% | $2.75M-24.2% | $3.62M+7.1% | $3.38M+35.1% | $2.5M-73.7% | ||
| -$183K— | —— | $98K+717% | $12K+157% | -$21K— | ||
| -$183K— | —— | $98K+717% | $12K+157% | -$21K— | ||
| —— | —— | —— | —— | —— | ||
| $6.39M-78.9% | $30.34M+2.0% | $29.73M+39.2% | $21.36M-76.0% | $89.01M+320% | ||
| -$83.36M-44.6% | -$57.64M-10.0% | -$52.41M+17.2% | -$63.28M-622% | $12.13M+124% | ||
| -$79.51M-47.9% | -$53.77M-10.8% | -$48.53M+18.3% | -$59.37M-469% | $16.08M+134% | ||
| -$79.51M-47.9% | -$53.77M-10.8% | -$48.53M+18.3% | -$59.37M-469% | $16.08M+134% | ||
| -1,243.6%-1,066pp | -177.2%-14.0pp | -163.2%+115pp | -278%-296pp | 18.1%+241pp | ||
| -$83.36M-44.6% | -$57.64M-10.0% | -$52.41M+17.2% | -$63.28M-622% | $12.13M+124% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Regenxbio's revenue?
- Regenxbio (RGNX) generated $87.8M in revenue over the trailing twelve months, down 44.0% year over year.
- Is Regenxbio profitable?
- Regenxbio is not currently profitable: it reported a net loss of $290.0M over the trailing twelve months, a -330.2% net margin.
- What are Regenxbio's profit margins?
- Gross margin is 59.7% and operating margin is -292.3%, with a -330.2% net margin.
- What is Regenxbio's earnings per share?
- Regenxbio's diluted EPS over the trailing twelve months is $-5.60.
- Where does Regenxbio's income statement data come from?
- Every line is extracted from Regenxbio's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
